In a notable turn of events, CVS Health recently reported fourth-quarter results that not only exceeded analysts’ expectations but also highlighted the complexities and challenges facing the retail drugstore chain as it navigates a tumultuous healthcare landscape. Under the leadership of newly appointed CEO David Joyner, who took the helm in mid-October, CVS is grappling with rising medical costs in its insurance segment, Aetna, while simultaneously trying to boost stock performance and profitability.
For the fourth quarter, CVS reported a revenue of $97.71 billion, surpassing the anticipated $97.19 billion, and adjusted earnings per share of $1.19, significantly higher than the expected 93 cents. This performance led to a more than 6% increase in shares during premarket trading, signaling some investor optimism amidst ongoing challenges. However, it is crucial to delve deeper into the underlying factors contributing to these figures, particularly the pressures on CVS’s insurance unit and the broader implications for the company’s future.
Despite the overall revenue growth—up 4.2% from the previous year—CVS’s net income fell to $1.64 billion, or $1.30 per share, down from $2.05 billion, or $1.58 per share, a year earlier. This decline in profitability can be traced back to increased medical costs and lower Medicare Advantage star ratings, which are critical metrics that help patients assess the quality of their Medicare health and drug plans. The star ratings for 2024 have notably impacted the operating results of CVS’s insurance business, leading to an adjusted operating loss of $439 million in the fourth quarter, a stark contrast to the adjusted operating income of $676 million reported a year prior.
The rise in medical costs is not an isolated issue for CVS; it reflects a broader trend seen across the healthcare sector. As more Medicare Advantage patients return to hospitals for previously deferred procedures, insurers have been grappling with escalating medical expenses. According to recent studies, this surge in demand for healthcare services post-pandemic has led to concerns about the sustainability of Medicare Advantage plans, which now cover more than half of all Medicare beneficiaries. With medical benefit ratios soaring to 94.8%—up from 88.5% the previous year—CVS’s insurance unit is facing increasing pressure to balance costs with revenue.
In terms of business segments, CVS’s health services division reported $47.02 billion in revenue, though this figure represented a decline of over 4% compared to the same quarter in 2023. This segment includes Caremark, one of the nation’s largest pharmacy benefit managers (PBMs). The decline can be attributed, in part, to the loss of a significant client, Tyson Foods, which recently transitioned to a different pharmacy benefit manager for its 140,000 employees. The implications of such client losses can be substantial, as they not only affect revenue but also the volume of processed pharmacy claims, which decreased from 600.8 million to 499.4 million over the year.
Conversely, CVS’s pharmacy and consumer wellness division saw a more positive trajectory, achieving $33.51 billion in sales—up more than 7% from the previous year. This growth was driven by an increase in prescription volume, although the unit still faced challenges from reimbursement pressures and decreased sales of front-of-store items, which are essential for overall retail health.
As CVS embarks on a turnaround plan involving $2 billion in cost cuts, the company’s management reshuffle under Joyner’s leadership reflects a proactive approach to addressing these multifaceted challenges. Analysts will be watching closely as CVS navigates its path forward, particularly in light of its full-year 2025 adjusted earnings outlook of $5.75 to $6 per share—an indication of cautious optimism that aligns with Wall Street’s expectations.
Ultimately, as CVS strives to enhance its profitability and stock performance in a competitive and increasingly complex healthcare environment, the focus will be on how effectively it can manage the rising costs within its insurance business while revitalizing its core retail operations. The company’s ability to adapt and respond to the changing dynamics of healthcare will likely determine its success in the years to come.
